FTC: Illumina/Grail the equivalent of pursuing a single covid-19 vaccine

Illumina’s recently-closed acquisition of Grail risks eliminating all competition for developing a blood test to screen for more than 50 types of cancers, the Federal Trade Commission has argued.


Get unlimited access to all Global Competition Review content